Abstract
Fluphenazine decanoate is commonly used as part of maintenance treatment of schizophrenia, but its pharmacokinetics are poorly understood. We administered a single intramuscular dose of fluphenazine decanoate to nine patients and found that plasma fluphenazine level did not decline to 50% of the peak level by day 26 in any of the patients. This means that it has a long half-life measurable in months rather than weeks.
MeSH terms
-
Adult
-
Chronic Disease
-
Drug Therapy, Combination
-
Fluphenazine / administration & dosage
-
Fluphenazine / analogs & derivatives*
-
Fluphenazine / pharmacokinetics
-
Haloperidol / administration & dosage
-
Haloperidol / pharmacokinetics
-
Humans
-
Injections, Intramuscular
-
Male
-
Metabolic Clearance Rate / physiology
-
Psychotic Disorders / blood*
-
Psychotic Disorders / drug therapy
Substances
-
fluphenazine depot
-
Haloperidol
-
Fluphenazine